Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 247

1.

Assessment of Immunogenicity and Efficacy of a Zika Vaccine Using Modified Vaccinia Ankara Virus as Carriers.

López-Camacho C, Kim YC, Abbink P, Larocca RA, Huiskonen JT, Barouch DH, Reyes-Sandoval A.

Pathogens. 2019 Nov 2;8(4). pii: E216. doi: 10.3390/pathogens8040216.

2.

Adenovirus Vector-Based Vaccines Confer Maternal-Fetal Protection against Zika Virus Challenge in Pregnant IFN-αβR-/- Mice.

Larocca RA, Mendes EA, Abbink P, Peterson RL, Martinot AJ, Iampietro MJ, Kang ZH, Aid M, Kirilova M, Jacob-Dolan C, Tostanoski L, Borducchi EN, De La Barrera RA, Barouch DH.

Cell Host Microbe. 2019 Nov 13;26(5):591-600.e4. doi: 10.1016/j.chom.2019.10.001. Epub 2019 Oct 24.

PMID:
31668877
3.

A microbial expression system for high-level production of scFv HIV-neutralizing antibody fragments in Escherichia coli.

Petrus MLC, Kiefer LA, Puri P, Heemskerk E, Seaman MS, Barouch DH, Arias S, van Wezel GP, Havenga M.

Appl Microbiol Biotechnol. 2019 Nov;103(21-22):8875-8888. doi: 10.1007/s00253-019-10145-1. Epub 2019 Oct 22.

PMID:
31641814
4.

A Meta-analysis of Passive Immunization Studies Shows that Serum-Neutralizing Antibody Titer Associates with Protection against SHIV Challenge.

Pegu A, Borate B, Huang Y, Pauthner MG, Hessell AJ, Julg B, Doria-Rose NA, Schmidt SD, Carpp LN, Cully MD, Chen X, Shaw GM, Barouch DH, Haigwood NL, Corey L, Burton DR, Roederer M, Gilbert PB, Mascola JR, Huang Y.

Cell Host Microbe. 2019 Sep 11;26(3):336-346.e3. doi: 10.1016/j.chom.2019.08.014.

PMID:
31513771
5.

Lack of therapeutic efficacy of an antibody to α4β7 in SIVmac251-infected rhesus macaques.

Abbink P, Mercado NB, Nkolola JP, Peterson RL, Tuyishime H, McMahan K, Moseley ET, Borducchi EN, Chandrashekar A, Bondzie EA, Agarwal A, Belli AJ, Reimann KA, Keele BF, Geleziunas R, Lewis MG, Barouch DH.

Science. 2019 Sep 6;365(6457):1029-1033. doi: 10.1126/science.aaw8562. Epub 2019 Sep 5.

PMID:
31488689
6.

A vaccine-induced gene expression signature correlates with protection against SIV and HIV in multiple trials.

Ehrenberg PK, Shangguan S, Issac B, Alter G, Geretz A, Izumi T, Bryant C, Eller MA, Wegmann F, Apps R, Creegan M, Bolton DL, Sekaly RP, Robb ML, Gramzinski RA, Pau MG, Schuitemaker H, Barouch DH, Michael NL, Thomas R.

Sci Transl Med. 2019 Aug 28;11(507). pii: eaaw4236. doi: 10.1126/scitranslmed.aaw4236.

PMID:
31462510
7.

HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design.

Bricault CA, Yusim K, Seaman MS, Yoon H, Theiler J, Giorgi EE, Wagh K, Theiler M, Hraber P, Macke JP, Kreider EF, Learn GH, Hahn BH, Scheid JF, Kovacs JM, Shields JL, Lavine CL, Ghantous F, Rist M, Bayne MG, Neubauer GH, McMahan K, Peng H, Chéneau C, Jones JJ, Zeng J, Ochsenbauer C, Nkolola JP, Stephenson KE, Chen B, Gnanakaran S, Bonsignori M, Williams LD, Haynes BF, Doria-Rose N, Mascola JR, Montefiori DC, Barouch DH, Korber B.

Cell Host Microbe. 2019 Aug 14;26(2):296. doi: 10.1016/j.chom.2019.07.016. No abstract available.

8.

The Landscape of Persistent Viral Genomes in ART-Treated SIV, SHIV, and HIV-2 Infections.

Bender AM, Simonetti FR, Kumar MR, Fray EJ, Bruner KM, Timmons AE, Tai KY, Jenike KM, Antar AAR, Liu PT, Ho YC, Raugi DN, Seydi M, Gottlieb GS, Okoye AA, Del Prete GQ, Picker LJ, Mankowski JL, Lifson JD, Siliciano JD, Laird GM, Barouch DH, Clements JE, Siliciano RF.

Cell Host Microbe. 2019 Jul 10;26(1):73-85.e4. doi: 10.1016/j.chom.2019.06.005.

PMID:
31295427
9.

Assessing the safety and pharmacokinetics of the monoclonal antibodies, VRC07-523LS and PGT121 in HIV negative women in South Africa: study protocol for the CAPRISA 012A randomised controlled phase I trial.

Mahomed S, Garrett N, Capparelli E, Baxter C, Zuma NY, Gengiah T, Archary D, Moore P, Samsunder N, Barouch DH, Mascola J, Ledgerwood J, Morris L, Abdool Karim S.

BMJ Open. 2019 Jul 3;9(7):e030283. doi: 10.1136/bmjopen-2019-030283.

10.

Neutralizing antibodies for HIV-1 prevention.

Julg B, Barouch DH.

Curr Opin HIV AIDS. 2019 Jul;14(4):318-324. doi: 10.1097/COH.0000000000000556.

PMID:
31082819
11.

Recommendations for analytical antiretroviral treatment interruptions in HIV research trials-report of a consensus meeting.

Julg B, Dee L, Ananworanich J, Barouch DH, Bar K, Caskey M, Colby DJ, Dawson L, Dong KL, Dubé K, Eron J, Frater J, Gandhi RT, Geleziunas R, Goulder P, Hanna GJ, Jefferys R, Johnston R, Kuritzkes D, Li JZ, Likhitwonnawut U, van Lunzen J, Martinez-Picado J, Miller V, Montaner LJ, Nixon DF, Palm D, Pantaleo G, Peay H, Persaud D, Salzwedel J, Salzwedel K, Schacker T, Sheikh V, Søgaard OS, Spudich S, Stephenson K, Sugarman J, Taylor J, Tebas P, Tiemessen CT, Tressler R, Weiss CD, Zheng L, Robb ML, Michael NL, Mellors JW, Deeks SG, Walker BD.

Lancet HIV. 2019 Apr;6(4):e259-e268. doi: 10.1016/S2352-3018(19)30052-9. Epub 2019 Mar 15. Review.

PMID:
30885693
12.

HIV-1 vaccination by needle-free oral injection induces strong mucosal immunity and protects against SHIV challenge.

Jones AT, Shen X, Walter KL, LaBranche CC, Wyatt LS, Tomaras GD, Montefiori DC, Moss B, Barouch DH, Clements JD, Kozlowski PA, Varadarajan R, Amara RR.

Nat Commun. 2019 Feb 18;10(1):798. doi: 10.1038/s41467-019-08739-4.

13.

HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design.

Bricault CA, Yusim K, Seaman MS, Yoon H, Theiler J, Giorgi EE, Wagh K, Theiler M, Hraber P, Macke JP, Kreider EF, Learn GH, Hahn BH, Scheid JF, Kovacs JM, Shields JL, Lavine CL, Ghantous F, Rist M, Bayne MG, Neubauer GH, McMahan K, Peng H, Chéneau C, Jones JJ, Zeng J, Ochsenbauer C, Nkolola JP, Stephenson KE, Chen B, Gnanakaran S, Bonsignori M, Williams LD, Haynes BF, Doria-Rose N, Mascola JR, Montefiori DC, Barouch DH, Korber B.

Cell Host Microbe. 2019 Jan 9;25(1):59-72.e8. doi: 10.1016/j.chom.2018.12.001. Erratum in: Cell Host Microbe. 2019 Aug 14;26(2):296.

14.

Prevention of SIVmac251 reservoir seeding in rhesus monkeys by early antiretroviral therapy.

Whitney JB, Lim SY, Osuna CE, Kublin JL, Chen E, Yoon G, Liu PT, Abbink P, Borducci EN, Hill A, Lewis MG, Geleziunas R, Robb ML, Michael NL, Barouch DH.

Nat Commun. 2018 Dec 21;9(1):5429. doi: 10.1038/s41467-018-07881-9.

15.

Vaccine-Induced Protection from Homologous Tier 2 SHIV Challenge in Nonhuman Primates Depends on Serum-Neutralizing Antibody Titers.

Pauthner MG, Nkolola JP, Havenar-Daughton C, Murrell B, Reiss SM, Bastidas R, Prévost J, Nedellec R, von Bredow B, Abbink P, Cottrell CA, Kulp DW, Tokatlian T, Nogal B, Bianchi M, Li H, Lee JH, Butera ST, Evans DT, Hangartner L, Finzi A, Wilson IA, Wyatt RT, Irvine DJ, Schief WR, Ward AB, Sanders RW, Crotty S, Shaw GM, Barouch DH, Burton DR.

Immunity. 2019 Jan 15;50(1):241-252.e6. doi: 10.1016/j.immuni.2018.11.011. Epub 2018 Dec 11.

16.

CMV Primes Functional Alternative Signaling in Adaptive Δg NK Cells but Is Subverted by Lentivirus Infection in Rhesus Macaques.

Shah SV, Manickam C, Ram DR, Kroll K, Itell H, Permar SR, Barouch DH, Klatt NR, Reeves RK.

Cell Rep. 2018 Dec 4;25(10):2766-2774.e3. doi: 10.1016/j.celrep.2018.11.020.

17.

First-in-human randomized controlled trial of an oral, replicating adenovirus 26 vector vaccine for HIV-1.

Stephenson KE, Keefer MC, Bunce CA, Frances D, Abbink P, Maxfield LF, Neubauer GH, Nkolola J, Peter L, Lane C, Park H, Verlinde C, Lombardo A, Yallop C, Havenga M, Fast P, Treanor J, Barouch DH.

PLoS One. 2018 Nov 14;13(11):e0205139. doi: 10.1371/journal.pone.0205139. eCollection 2018.

18.

Publisher Correction: Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys.

Borducchi EN, Liu J, Nkolola JP, Cadena AM, Yu WH, Fischinger S, Broge T, Abbink P, Mercado NB, Chandrashekar A, Jetton D, Peter L, McMahan K, Moseley ET, Bekerman E, Hesselgesser J, Li W, Lewis MG, Alter G, Geleziunas R, Barouch DH.

Nature. 2018 Dec;564(7734):E8. doi: 10.1038/s41586-018-0721-y.

PMID:
30397346
19.

Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys.

Borducchi EN, Liu J, Nkolola JP, Cadena AM, Yu WH, Fischinger S, Broge T, Abbink P, Mercado NB, Chandrashekar A, Jetton D, Peter L, McMahan K, Moseley ET, Bekerman E, Hesselgesser J, Li W, Lewis MG, Alter G, Geleziunas R, Barouch DH.

Nature. 2018 Nov;563(7731):360-364. doi: 10.1038/s41586-018-0600-6. Epub 2018 Oct 3. Erratum in: Nature. 2018 Nov 5;:.

20.

Combined HDAC and BET Inhibition Enhances Melanoma Vaccine Immunogenicity and Efficacy.

Badamchi-Zadeh A, Moynihan KD, Larocca RA, Aid M, Provine NM, Iampietro MJ, Kinnear E, Penaloza-MacMaster P, Abbink P, Blass E, Tregoning JS, Irvine DJ, Barouch DH.

J Immunol. 2018 Nov 1;201(9):2744-2752. doi: 10.4049/jimmunol.1800885. Epub 2018 Sep 24.

21.

Adenoviral vector type 26 encoding Zika virus (ZIKV) M-Env antigen induces humoral and cellular immune responses and protects mice and nonhuman primates against ZIKV challenge.

Cox F, van der Fits L, Abbink P, Larocca RA, van Huizen E, Saeland E, Verhagen J, Peterson R, Tolboom J, Kaufmann B, Schuitemaker H, Barouch DH, Zahn R.

PLoS One. 2018 Aug 24;13(8):e0202820. doi: 10.1371/journal.pone.0202820. eCollection 2018.

22.

Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19).

Barouch DH, Tomaka FL, Wegmann F, Stieh DJ, Alter G, Robb ML, Michael NL, Peter L, Nkolola JP, Borducchi EN, Chandrashekar A, Jetton D, Stephenson KE, Li W, Korber B, Tomaras GD, Montefiori DC, Gray G, Frahm N, McElrath MJ, Baden L, Johnson J, Hutter J, Swann E, Karita E, Kibuuka H, Mpendo J, Garrett N, Mngadi K, Chinyenze K, Priddy F, Lazarus E, Laher F, Nitayapan S, Pitisuttithum P, Bart S, Campbell T, Feldman R, Lucksinger G, Borremans C, Callewaert K, Roten R, Sadoff J, Scheppler L, Weijtens M, Feddes-de Boer K, van Manen D, Vreugdenhil J, Zahn R, Lavreys L, Nijs S, Tolboom J, Hendriks J, Euler Z, Pau MG, Schuitemaker H.

Lancet. 2018 Jul 21;392(10143):232-243. doi: 10.1016/S0140-6736(18)31364-3. Epub 2018 Jul 6.

23.

T-cell subset differentiation and antibody responses following antiretroviral therapy during simian immunodeficiency virus infection.

Bhattacharyya M, Whitney JB, Seaman M, Barouch DH, Penaloza-MacMaster P.

Immunology. 2018 Dec;155(4):458-466. doi: 10.1111/imm.12985. Epub 2018 Aug 14.

PMID:
30014618
24.

Rational Zika vaccine design via the modulation of antigen membrane anchors in chimpanzee adenoviral vectors.

López-Camacho C, Abbink P, Larocca RA, Dejnirattisai W, Boyd M, Badamchi-Zadeh A, Wallace ZR, Doig J, Velazquez RS, Neto RDL, Coelho DF, Kim YC, Donald CL, Owsianka A, De Lorenzo G, Kohl A, Gilbert SC, Dorrell L, Mongkolsapaya J, Patel AH, Screaton GR, Barouch DH, Hill AVS, Reyes-Sandoval A.

Nat Commun. 2018 Jun 22;9(1):2441. doi: 10.1038/s41467-018-04859-5.

25.

Zika virus vaccines.

Abbink P, Stephenson KE, Barouch DH.

Nat Rev Microbiol. 2018 Oct;16(10):594-600. doi: 10.1038/s41579-018-0039-7. Review.

26.

A step forward for HIV vaccines.

Barouch DH.

Lancet HIV. 2018 Jul;5(7):e338-e339. doi: 10.1016/S2352-3018(18)30095-X. Epub 2018 Jun 10. No abstract available.

27.

Therapeutic and protective efficacy of a dengue antibody against Zika infection in rhesus monkeys.

Abbink P, Larocca RA, Dejnirattisai W, Peterson R, Nkolola JP, Borducchi EN, Supasa P, Mongkolsapaya J, Screaton GR, Barouch DH.

Nat Med. 2018 Jun;24(6):721-723. doi: 10.1038/s41591-018-0056-0. Epub 2018 Jun 4.

28.

Similar Epitope Specificities of IgG and IgA Antibodies Elicited by Ad26 Vector Prime, Env Protein Boost Immunizations in Rhesus Monkeys.

Kang ZH, Bricault CA, Borducchi EN, Stephenson KE, Seaman MS, Pau M, Schuitemaker H, van Manen D, Wegmann F, Barouch DH.

J Virol. 2018 Jul 17;92(15). pii: e00537-18. doi: 10.1128/JVI.00537-18. Print 2018 Aug 1.

29.

First-in-Human Randomized, Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector.

Baden LR, Walsh SR, Seaman MS, Cohen YZ, Johnson JA, Licona JH, Filter RD, Kleinjan JA, Gothing JA, Jennings J, Peter L, Nkolola J, Abbink P, Borducchi EN, Kirilova M, Stephenson KE, Pegu P, Eller MA, Trinh HV, Rao M, Ake JA, Sarnecki M, Nijs S, Callewaert K, Schuitemaker H, Hendriks J, Pau MG, Tomaka F, Korber BT, Alter G, Dolin R, Earl PL, Moss B, Michael NL, Robb ML, Barouch DH; IPCAVD006/RV380/HIV-V-A002 Study Group.

J Infect Dis. 2018 Jul 13;218(4):633-644. doi: 10.1093/infdis/jiy212.

30.

Neutralizing Antibody Responses following Long-Term Vaccination with HIV-1 Env gp140 in Guinea Pigs.

Bricault CA, Kovacs JM, Badamchi-Zadeh A, McKee K, Shields JL, Gunn BM, Neubauer GH, Ghantous F, Jennings J, Gillis L, Perry J, Nkolola JP, Alter G, Chen B, Stephenson KE, Doria-Rose N, Mascola JR, Seaman MS, Barouch DH.

J Virol. 2018 Jun 13;92(13). pii: e00369-18. doi: 10.1128/JVI.00369-18. Print 2018 Jul 1.

31.

Fetal Neuropathology in Zika Virus-Infected Pregnant Female Rhesus Monkeys.

Martinot AJ, Abbink P, Afacan O, Prohl AK, Bronson R, Hecht JL, Borducchi EN, Larocca RA, Peterson RL, Rinaldi W, Ferguson M, Didier PJ, Weiss D, Lewis MG, De La Barrera RA, Yang E, Warfield SK, Barouch DH.

Cell. 2018 May 17;173(5):1111-1122.e10. doi: 10.1016/j.cell.2018.03.019. Epub 2018 Mar 29.

32.

Immunogenicity and Cross-Reactivity of Rhesus Adenoviral Vectors.

Iampietro MJ, Larocca RA, Provine NM, Abbink P, Kang ZH, Bricault CA, Barouch DH.

J Virol. 2018 May 14;92(11). pii: e00159-18. doi: 10.1128/JVI.00159-18. Print 2018 Jun 1.

33.

Corrigendum: An immunogenic personal neoantigen vaccine for patients with melanoma.

Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ, Zhang W, Luoma A, Giobbie-Hurder A, Peter L, Chen C, Olive O, Carter TA, Li S, Lieb DJ, Eisenhaure T, Gjini E, Stevens J, Lane WJ, Javeri I, Nellaiappan K, Salazar AM, Daley H, Seaman M, Buchbinder EI, Yoon CH, Harden M, Lennon N, Gabriel S, Rodig SJ, Barouch DH, Aster JC, Getz G, Wucherpfennig K, Neuberg D, Ritz J, Lander ES, Fritsch EF, Hacohen N, Wu CJ.

Nature. 2018 Mar 14;555(7696):402. doi: 10.1038/nature25145.

34.

Adenovirus Vector Vaccination Impacts NK Cell Rheostat Function following Lymphocytic Choriomeningitis Virus Infection.

Blass E, Aid M, Martinot AJ, Larocca RA, Kang ZH, Badamchi-Zadeh A, Penaloza-MacMaster P, Reeves RK, Barouch DH.

J Virol. 2018 May 14;92(11). pii: e02103-17. doi: 10.1128/JVI.02103-17. Print 2018 Jun 1.

35.

Potential of conventional & bispecific broadly neutralizing antibodies for prevention of HIV-1 subtype A, C & D infections.

Wagh K, Seaman MS, Zingg M, Fitzsimons T, Barouch DH, Burton DR, Connors M, Ho DD, Mascola JR, Nussenzweig MC, Ravetch J, Gautam R, Martin MA, Montefiori DC, Korber B.

PLoS Pathog. 2018 Mar 5;14(3):e1006860. doi: 10.1371/journal.ppat.1006860. eCollection 2018 Mar.

36.

Epitopes for neutralizing antibodies induced by HIV-1 envelope glycoprotein BG505 SOSIP trimers in rabbits and macaques.

Klasse PJ, Ketas TJ, Cottrell CA, Ozorowski G, Debnath G, Camara D, Francomano E, Pugach P, Ringe RP, LaBranche CC, van Gils MJ, Bricault CA, Barouch DH, Crotty S, Silvestri G, Kasturi S, Pulendran B, Wilson IA, Montefiori DC, Sanders RW, Ward AB, Moore JP.

PLoS Pathog. 2018 Feb 23;14(2):e1006913. doi: 10.1371/journal.ppat.1006913. eCollection 2018 Feb.

37.

Optimization and qualification of an Fc Array assay for assessments of antibodies against HIV-1/SIV.

Brown EP, Weiner JA, Lin S, Natarajan H, Normandin E, Barouch DH, Alter G, Sarzotti-Kelsoe M, Ackerman ME.

J Immunol Methods. 2018 Apr;455:24-33. doi: 10.1016/j.jim.2018.01.013. Epub 2018 Jan 31.

38.

Therapeutic Efficacy of Vectored PGT121 Gene Delivery in HIV-1-Infected Humanized Mice.

Badamchi-Zadeh A, Tartaglia LJ, Abbink P, Bricault CA, Liu PT, Boyd M, Kirilova M, Mercado NB, Nanayakkara OS, Vrbanac VD, Tager AM, Larocca RA, Seaman MS, Barouch DH.

J Virol. 2018 Mar 14;92(7). pii: e01925-17. doi: 10.1128/JVI.01925-17. Print 2018 Apr 1.

39.

Rapid Cloning of Novel Rhesus Adenoviral Vaccine Vectors.

Abbink P, Kirilova M, Boyd M, Mercado N, Li Z, Nityanandam R, Nanayakkara O, Peterson R, Larocca RA, Aid M, Tartaglia L, Mutetwa T, Blass E, Jetton D, Maxfield LF, Borducchi EN, Badamchi-Zadeh A, Handley S, Zhao G, Virgin HW, Havenga MJ, Barouch DH.

J Virol. 2018 Feb 26;92(6). pii: e01924-17. doi: 10.1128/JVI.01924-17. Print 2018 Mar 15.

40.

Initiation of Antiviral B Cell Immunity Relies on Innate Signals from Spatially Positioned NKT Cells.

Gaya M, Barral P, Burbage M, Aggarwal S, Montaner B, Warren Navia A, Aid M, Tsui C, Maldonado P, Nair U, Ghneim K, Fallon PG, Sekaly RP, Barouch DH, Shalek AK, Bruckbauer A, Strid J, Batista FD.

Cell. 2018 Jan 25;172(3):517-533.e20. doi: 10.1016/j.cell.2017.11.036. Epub 2017 Dec 14.

41.

Durability and correlates of vaccine protection against Zika virus in rhesus monkeys.

Abbink P, Larocca RA, Visitsunthorn K, Boyd M, De La Barrera RA, Gromowski GD, Kirilova M, Peterson R, Li Z, Nanayakkara O, Nityanandam R, Mercado NB, Borducchi EN, Chandrashekar A, Jetton D, Mojta S, Gandhi P, LeSuer J, Khatiwada S, Lewis MG, Modjarrad K, Jarman RG, Eckels KH, Thomas SJ, Michael NL, Barouch DH.

Sci Transl Med. 2017 Dec 13;9(420). pii: eaao4163. doi: 10.1126/scitranslmed.aao4163. Erratum in: Sci Transl Med. 2018 Jul 18;10(450):.

42.

Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials.

Modjarrad K, Lin L, George SL, Stephenson KE, Eckels KH, De La Barrera RA, Jarman RG, Sondergaard E, Tennant J, Ansel JL, Mills K, Koren M, Robb ML, Barrett J, Thompson J, Kosel AE, Dawson P, Hale A, Tan CS, Walsh SR, Meyer KE, Brien J, Crowell TA, Blazevic A, Mosby K, Larocca RA, Abbink P, Boyd M, Bricault CA, Seaman MS, Basil A, Walsh M, Tonwe V, Hoft DF, Thomas SJ, Barouch DH, Michael NL.

Lancet. 2018 Feb 10;391(10120):563-571. doi: 10.1016/S0140-6736(17)33106-9. Epub 2017 Dec 5.

43.

HIV-1 Latency by Transition.

Julg B, Barouch DH.

Immunity. 2017 Oct 17;47(4):611-612. doi: 10.1016/j.immuni.2017.09.019.

44.

Novel vaccine vectors for HIV-1.

Barouch DH, Picker LJ.

Nat Rev Microbiol. 2017 Oct 12;15(11):696. doi: 10.1038/nrmicro.2017.134. No abstract available.

PMID:
29021601
45.

Protection against a mixed SHIV challenge by a broadly neutralizing antibody cocktail.

Julg B, Liu PT, Wagh K, Fischer WM, Abbink P, Mercado NB, Whitney JB, Nkolola JP, McMahan K, Tartaglia LJ, Borducchi EN, Khatiwada S, Kamath M, LeSuer JA, Seaman MS, Schmidt SD, Mascola JR, Burton DR, Korber BT, Barouch DH.

Sci Transl Med. 2017 Sep 20;9(408). pii: eaao4235. doi: 10.1126/scitranslmed.aao4235.

46.

Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques.

Xu L, Pegu A, Rao E, Doria-Rose N, Beninga J, McKee K, Lord DM, Wei RR, Deng G, Louder M, Schmidt SD, Mankoff Z, Wu L, Asokan M, Beil C, Lange C, Leuschner WD, Kruip J, Sendak R, Kwon YD, Zhou T, Chen X, Bailer RT, Wang K, Choe M, Tartaglia LJ, Barouch DH, O'Dell S, Todd JP, Burton DR, Roederer M, Connors M, Koup RA, Kwong PD, Yang ZY, Mascola JR, Nabel GJ.

Science. 2017 Oct 6;358(6359):85-90. doi: 10.1126/science.aan8630. Epub 2017 Sep 20.

47.

Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge.

Julg B, Tartaglia LJ, Keele BF, Wagh K, Pegu A, Sok D, Abbink P, Schmidt SD, Wang K, Chen X, Joyce MG, Georgiev IS, Choe M, Kwong PD, Doria-Rose NA, Le K, Louder MK, Bailer RT, Moore PL, Korber B, Seaman MS, Abdool Karim SS, Morris L, Koup RA, Mascola JR, Burton DR, Barouch DH.

Sci Transl Med. 2017 Sep 6;9(406). pii: eaal1321. doi: 10.1126/scitranslmed.aal1321.

48.

Impact of prior flavivirus immunity on Zika virus infection in rhesus macaques.

McCracken MK, Gromowski GD, Friberg HL, Lin X, Abbink P, De La Barrera R, Eckles KH, Garver LS, Boyd M, Jetton D, Barouch DH, Wise MC, Lewis BS, Currier JR, Modjarrad K, Milazzo M, Liu M, Mullins AB, Putnak JR, Michael NL, Jarman RG, Thomas SJ.

PLoS Pathog. 2017 Aug 3;13(8):e1006487. doi: 10.1371/journal.ppat.1006487. eCollection 2017 Aug.

49.

Protective Efficacy of Broadly Neutralizing Antibodies with Incomplete Neutralization Activity against Simian-Human Immunodeficiency Virus in Rhesus Monkeys.

Julg B, Sok D, Schmidt SD, Abbink P, Newman RM, Broge T, Linde C, Nkolola J, Le K, Su D, Torabi J, Pack M, Pegu A, Allen TM, Mascola JR, Burton DR, Barouch DH.

J Virol. 2017 Sep 27;91(20). pii: e01187-17. doi: 10.1128/JVI.01187-17. Print 2017 Oct 15.

50.

An immunogenic personal neoantigen vaccine for patients with melanoma.

Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ, Zhang W, Luoma A, Giobbie-Hurder A, Peter L, Chen C, Olive O, Carter TA, Li S, Lieb DJ, Eisenhaure T, Gjini E, Stevens J, Lane WJ, Javeri I, Nellaiappan K, Salazar AM, Daley H, Seaman M, Buchbinder EI, Yoon CH, Harden M, Lennon N, Gabriel S, Rodig SJ, Barouch DH, Aster JC, Getz G, Wucherpfennig K, Neuberg D, Ritz J, Lander ES, Fritsch EF, Hacohen N, Wu CJ.

Nature. 2017 Jul 13;547(7662):217-221. doi: 10.1038/nature22991. Epub 2017 Jul 5. Erratum in: Nature. 2018 Mar 14;555(7696):402.

Supplemental Content

Loading ...
Support Center